MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Akebia Therapeutics DPO Ratio 2011-2026 | AKBA
Annual DPO Ratio Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 168 | 86.1 | 80.4 | 110 | 90.7 | 49.6 | 98.5 | 2.01 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.01 K | 49.6 | 337 |
Quarterly DPO Ratio Akebia Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 | 111 | 167 | - | 76 | - | - | - | 52.7 | 64.3 | 71.7 | - | 23.5 | 47.8 | 77.2 | - | 203 | 63 | 94.7 | 59.6 | 124 | 21.6 | 133 | 93.8 | 93.5 | 95 | 120 | 503 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 503 | 21.6 | 109 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Xeris Pharmaceuticals
XERS
|
23 | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
338 | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
1.34 K | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
6.01 K | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | Israel |
 |
Agios Pharmaceuticals
AGIO
|
1.01 K | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
30.3 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
306 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
13.8 | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Teligent, Inc.
TLGT
|
59.2 | - | -13.85 % | $ 16.1 M | USA |
 |
Evogene Ltd.
EVGN
|
62.6 | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
997 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
190 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
65.5 | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
104 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
0.173 | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.83 | 5.37 % | $ 4.53 M | China |